Atkins MB - Search Results

1

Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.

Zhang L, Bhasin M, Schor-Bardach R, Wang X, Collins MP, Panka D, Putheti P, Signoretti S, Alsop DC, Libermann T, Atkins MB, Mier JW, Goldberg SN, Bhatt RS. Zhang L, et al. Among authors: atkins mb. PLoS One. 2011 Apr 29;6(4):e19144. doi: 10.1371/journal.pone.0019144. PLoS One. 2011. PMID: 21559452 Free PMC article.

2

Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy.

Atkins MB, Vachino G, Tilg HJ, Karp DD, Robert NJ, Kappler K, Mier JW. Atkins MB, et al. J Clin Oncol. 1992 Nov;10(11):1802-9. doi: 10.1200/JCO.1992.10.11.1802. J Clin Oncol. 1992. PMID: 1403061 Clinical Trial.

3

Chest roentgenographic abnormalities in IL-2 recipients. Incidence and correlation with clinical parameters.

Vogelzang PJ, Bloom SM, Mier JW, Atkins MB. Vogelzang PJ, et al. Among authors: atkins mb. Chest. 1992 Mar;101(3):746-52. doi: 10.1378/chest.101.3.746. Chest. 1992. PMID: 1541142

4

Transient thyrotoxicosis and persistent hypothyroidism due to acute autoimmune thyroiditis after interleukin-2 and interferon-alpha therapy for metastatic carcinoma: a case report.

Sauter NP, Atkins MB, Mier JW, Lechan RM. Sauter NP, et al. Among authors: atkins mb. Am J Med. 1992 Apr;92(4):441-4. doi: 10.1016/0002-9343(92)90278-j. Am J Med. 1992. PMID: 1558092

5

Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy.

Massarotti EM, Liu NY, Mier J, Atkins MB. Massarotti EM, et al. Among authors: atkins mb. Am J Med. 1992 Jun;92(6):693-7. doi: 10.1016/0002-9343(92)90789-e. Am J Med. 1992. PMID: 1605152

6

Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study.

Demchak PA, Mier JW, Robert NJ, O'Brien K, Gould JA, Atkins MB. Demchak PA, et al. Among authors: atkins mb. J Clin Oncol. 1991 Oct;9(10):1821-30. doi: 10.1200/JCO.1991.9.10.1821. J Clin Oncol. 1991. PMID: 1655988

7

Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes.

Vachino G, Gelfand JA, Atkins MB, Tamerius JD, Demchak P, Mier JW. Vachino G, et al. Among authors: atkins mb. Blood. 1991 Nov 15;78(10):2505-13. Blood. 1991. PMID: 1824247 Free article.

8

Augmentation of insulin autoantibodies following interleukin-2 and lymphokine activated killer cell therapy.

Bergstrom RW, Atkins MB, Mier JW, Palmer JP. Bergstrom RW, et al. Among authors: atkins mb. J Clin Lab Immunol. 1990 Apr;31(4):189-93. J Clin Lab Immunol. 1990. PMID: 1967063

9

An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy.

Klempner MS, Noring R, Mier JW, Atkins MB. Klempner MS, et al. Among authors: atkins mb. N Engl J Med. 1990 Apr 5;322(14):959-65. doi: 10.1056/NEJM199004053221404. N Engl J Med. 1990. PMID: 2156163 Free article.

10

Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects.

Mier JW, Vachino G, Klempner MS, Aronson FR, Noring R, Smith S, Brandon EP, Laird W, Atkins MB. Mier JW, et al. Among authors: atkins mb. Blood. 1990 Nov 15;76(10):1933-40. Blood. 1990. PMID: 2242421 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

477 results

Search Page

Filters